Management of T1 Hormone Receptor-Positive, HER2-Negative Breast Cancer in Perimenopausal Women

Introduction to Management

The National Comprehensive Cancer Network recommends breast-conserving surgery with radiation therapy followed by adjuvant endocrine therapy, with consideration of chemotherapy based on tumor characteristics and genomic testing for perimenopausal women with T1 hormone receptor-positive, HER2-negative breast cancer 1, 2

Breast-conserving surgery with radiation therapy is the preferred approach for T1 tumors, offering equivalent survival outcomes to mastectomy while preserving breast tissue, as recommended by the National Comprehensive Cancer Network 2, 3
Sentinel lymph node biopsy should be performed for axillary staging in clinically node-negative disease, avoiding the morbidity associated with axillary lymph node dissection, according to the National Comprehensive Cancer Network 2
For patients with 1-2 positive sentinel lymph nodes who will receive whole breast radiation therapy, completion axillary lymph node dissection can be omitted based on the ACOSOG Z0011 trial results, as stated by the National Comprehensive Cancer Network 2, 4

Whole breast radiation therapy following breast-conserving surgery is standard of care, reducing local recurrence and improving survival, as recommended by the National Comprehensive Cancer Network 1, 2
Regional nodal irradiation should be considered for patients with positive lymph nodes, as it has been shown to improve disease-free survival, according to the National Comprehensive Cancer Network 5
Radiation therapy can be delivered sequentially or concurrently with endocrine therapy, as stated by the National Comprehensive Cancer Network 1, 4

Adjuvant endocrine therapy is indicated for all hormone receptor-positive breast cancers, as recommended by the National Comprehensive Cancer Network (category 1 recommendation) 1, 4
For perimenopausal women, treatment options include tamoxifen for 5-10 years, as recommended by the National Comprehensive Cancer Network 4, 5
Ovarian suppression plus an aromatase inhibitor may be considered for higher-risk patients, according to the National Comprehensive Cancer Network and the American Society of Clinical Oncology 5, 6

For T1b-c, node-negative tumors, genomic assays should be used to assess recurrence risk and guide chemotherapy decisions, as recommended by the National Comprehensive Cancer Network 4
Patients with low recurrence scores can be treated with endocrine therapy alone, according to the National Comprehensive Cancer Network 4
Patients with high recurrence scores should receive chemotherapy followed by endocrine therapy, as stated by the National Comprehensive Cancer Network 4

Careful assessment of menopausal status is essential as it affects treatment choices, as recommended by the National Comprehensive Cancer Network and the American College of Obstetricians and Gynecologists 1, 7
Hormone replacement therapy is contraindicated in women with hormone receptor-positive breast cancer due to increased risk of recurrence, as stated by the American College of Obstetricians and Gynecologists 7

Underestimating the importance of endocrine therapy in small T1 tumors, as recommended by the National Comprehensive Cancer Network 1
Overtreatment with chemotherapy for low-risk T1 tumors with favorable genomic profiles, according to the National Comprehensive Cancer Network 4
Failing to address menopausal symptoms, which can lead to poor adherence to endocrine therapy, as stated by the American College of Obstetricians and Gynecologists 7